ARTICLE | Clinical News
Sycrest regulatory update
September 6, 2010 7:00 AM UTC
The European Commission approved an MAA from Merck for Sycrest asenapine to treat moderate to severe manic episodes associated with bipolar I disorder. Merck markets the serotonin (5-HT2) and dopamine...